iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Stock Short Interest Falls 55.2%

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) saw a significant decline in short interest in September. As of September 15th, there was short interest totaling 23,081 shares, a decline of 55.2% from the August 31st total of 51,524 shares. Based on an average daily volume of 151,159 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.3% of the shares of the stock are sold short.

iShares Genomics Immunology and Healthcare ETF Stock Performance

IDNA traded up $0.23 on Wednesday, reaching $42.86. The company had a trading volume of 213,167 shares, compared to its average volume of 62,122. The business has a 50 day simple moving average of $37.51 and a 200 day simple moving average of $32.89. The company has a market cap of $293.59 million, a price-to-earnings ratio of 14.76 and a beta of 0.95. iShares Genomics Immunology and Healthcare ETF has a 52-week low of $23.71 and a 52-week high of $42.97.

Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF

An institutional investor recently bought a new position in iShares Genomics Immunology and Healthcare ETF stock. NewEdge Advisors LLC acquired a new position in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 961 shares of the company’s stock, valued at approximately $32,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.